Pyridam Farma Tbk PT
IDX:PYFA
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
89
1 400
|
Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PYFA stock under the Base Case scenario is 113.82 IDR. Compared to the current market price of 264 IDR, Pyridam Farma Tbk PT is Overvalued by 57%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Pyridam Farma Tbk PT
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PYFA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Pyridam Farma Tbk PT
Balance Sheet Decomposition
Pyridam Farma Tbk PT
Current Assets | 1.7T |
Cash & Short-Term Investments | 505.4B |
Receivables | 617.5B |
Other Current Assets | 589.9B |
Non-Current Assets | 4.2T |
Long-Term Investments | 99.7B |
PP&E | 1.5T |
Intangibles | 2.5T |
Other Non-Current Assets | 21.1B |
Current Liabilities | 2.3T |
Accounts Payable | 303.6B |
Accrued Liabilities | 98.5B |
Short-Term Debt | 1.7T |
Other Current Liabilities | 184.3B |
Non-Current Liabilities | 2.4T |
Long-Term Debt | 2.1T |
Other Non-Current Liabilities | 291.3B |
Earnings Waterfall
Pyridam Farma Tbk PT
Revenue
|
1.3T
IDR
|
Cost of Revenue
|
-975.6B
IDR
|
Gross Profit
|
367.9B
IDR
|
Operating Expenses
|
-495.7B
IDR
|
Operating Income
|
-127.8B
IDR
|
Other Expenses
|
-126.2B
IDR
|
Net Income
|
-254B
IDR
|
Free Cash Flow Analysis
Pyridam Farma Tbk PT
IDR | |
Free Cash Flow | IDR |
PYFA Profitability Score
Profitability Due Diligence
Pyridam Farma Tbk PT's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Pyridam Farma Tbk PT's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
PYFA Solvency Score
Solvency Due Diligence
Pyridam Farma Tbk PT's solvency score is 19/100. The higher the solvency score, the more solvent the company is.
Score
Pyridam Farma Tbk PT's solvency score is 19/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PYFA Price Targets Summary
Pyridam Farma Tbk PT
Dividends
Current shareholder yield for PYFA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
PT Pyridam Farma Tbk engages in the production and development of pharmaceutical medicines, and trading of medical supplies. The company is headquartered in Jakarta, Dki Jakarta and currently employs 1,539 full-time employees. The company went IPO on 2001-10-16. The firm operates through two segments: Pharmaceutical Products and Toll Manufacturing Services, and Medical Device Products. Its business consists of production and/or distribution of modern and traditional medicines and distribution of medical devices, such as laboratory equipment and PCR test kits. The company offers products across consumer health, prescription, pyfaesthetic and biomedilab categories. The company produces various kinds of pharmaceuticals products ranging from antibiotics, vitamins and health supplements. The firm offers its products in the form of effervescent tablets, capsules, caplets, syrups and creams. Its prescription production has several properties, such as anti-infection, anti-inflammatory, anti-parkinsonian, anti-epileptic, and other indications. The company provides toll manufacturing services to produce products owned by the Company’s partner companies in accordance with predetermined specifications.
Contact
IPO
Employees
Officers
The intrinsic value of one PYFA stock under the Base Case scenario is 113.82 IDR.
Compared to the current market price of 264 IDR, Pyridam Farma Tbk PT is Overvalued by 57%.